Jorge Cortes Selected Research

Residual Neoplasm

2/2018	Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial.
12/2017	Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia.
9/2017	Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia.
4/2017	Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation.
3/2017	Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission.
2/2017	Frontline treatment of acute myeloid leukemia in adults.
1/2017	Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.
1/2017	Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia.
10/2012	Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure.
2/2011	Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jorge Cortes Research Topics

Disease

271	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 03/2024 - 03/2002
137	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 03/2024 - 08/2002
77	Neoplasms (Cancer) 01/2023 - 10/2002
71	Philadelphia Chromosome 11/2022 - 04/2002
70	Leukemia 01/2022 - 03/2002
67	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2023 - 07/2002
61	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 11/2022 - 03/2002
32	Primary Myelofibrosis (Myelosclerosis) 11/2021 - 03/2003
30	Blast Crisis (Blast Phase) 01/2021 - 05/2002
22	Hematologic Neoplasms (Hematological Malignancy) 05/2020 - 10/2002
19	Acute Promyelocytic Leukemia 01/2019 - 05/2003
18	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 05/2015 - 04/2003
16	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 01/2023 - 06/2003
16	Residual Neoplasm 02/2018 - 01/2003
13	Anemia 01/2021 - 04/2002
13	Chromosome Aberrations (Chromosome Abnormalities) 01/2018 - 05/2002
13	Myeloid Leukemia (Leukemia, Myelocytic) 04/2015 - 04/2006
12	Thrombocytopenia (Thrombopenia) 11/2021 - 06/2004
10	Polycythemia Vera 04/2017 - 06/2003
10	Myeloproliferative Disorders (Myeloproliferative Disorder) 06/2008 - 10/2002
9	Neutropenia 01/2023 - 06/2003
9	Pathologic Complete Response 01/2019 - 01/2003
9	Disease Progression 04/2018 - 05/2002
7	Exanthema (Rash) 01/2021 - 06/2009
7	Diarrhea 01/2021 - 08/2002
7	Lymphoma (Lymphomas) 01/2019 - 12/2003
7	Infections 12/2018 - 03/2003
7	Nausea 09/2018 - 10/2002
7	Splenomegaly 01/2018 - 06/2010
7	Essential Thrombocythemia 08/2013 - 01/2003
6	Hemorrhage 12/2018 - 06/2009
6	Fibrosis (Cirrhosis) 07/2018 - 07/2004
6	Multiple Myeloma 01/2016 - 03/2003
6	Hypereosinophilic Syndrome (Loeffler Endocarditis) 06/2013 - 09/2002
5	Fatigue 01/2021 - 01/2003
5	Sepsis (Septicemia) 12/2017 - 11/2004
5	Leukocytosis (Pleocytosis) 01/2017 - 12/2003
5	Systemic Mastocytosis 09/2013 - 05/2004
4	Pneumonia (Pneumonitis) 01/2023 - 01/2003
4	Hypertension (High Blood Pressure) 01/2023 - 11/2015
4	Pleural Effusion (Pleural Effusions) 01/2020 - 09/2007

Drug/Important Bio-Agent (IBA)

174	Imatinib Mesylate (Gleevec)FDA Link 01/2020 - 05/2002
124	Tyrosine Kinase InhibitorsIBA 03/2024 - 09/2003
42	Dasatinib (BMS 354825)FDA Link 11/2020 - 06/2006
42	Cytarabine (Cytosar-U)FDA LinkGeneric 10/2019 - 03/2002
34	Phosphotransferases (Kinase)IBA 01/2018 - 12/2003
32	nilotinib FDA Link 01/2020 - 07/2005
21	Proteins (Proteins, Gene)FDA Link 01/2021 - 03/2002
20	Decitabine FDA Link 01/2021 - 08/2003
16	bcr-abl Fusion ProteinsIBA 01/2020 - 06/2004
15	ponatinibIBA 01/2024 - 06/2013
15	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2019 - 05/2003
15	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2018 - 03/2002
15	InterferonsIBA 10/2013 - 06/2003
14	Interferon-alpha (Interferon Alfa)IBA 06/2012 - 04/2002
13	Vincristine (Oncovin)FDA LinkGeneric 01/2020 - 03/2002
13	HomoharringtonineIBA 01/2017 - 04/2002
12	fludarabineIBA 01/2018 - 03/2003
12	Rituximab (Mabthera)FDA Link 02/2015 - 04/2003
11	Monoclonal AntibodiesIBA 01/2021 - 12/2003
11	fms-Like Tyrosine Kinase 3IBA 01/2021 - 02/2008
11	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 01/2017 - 08/2002
10	ruxolitinibIBA 11/2021 - 11/2011
10	Arsenic Trioxide (Trisenox)FDA Link 01/2019 - 05/2003
10	Clofarabine (Clolar)FDA Link 07/2015 - 03/2003
9	Azacitidine (5 Azacytidine)FDA Link 01/2023 - 10/2007
9	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 11/2021 - 05/2004
9	Hemoglobins (Hemoglobin)IBA 01/2021 - 04/2002
9	Dexamethasone (Maxidex)FDA LinkGeneric 05/2015 - 03/2002
8	Prednisone (Sone)FDA LinkGeneric 12/2018 - 10/2009
8	Gemtuzumab (Mylotarg)FDA Link 02/2017 - 12/2002
8	NucleosidesIBA 06/2014 - 12/2003
7	Core Binding Factors (Core-Binding Factor)IBA 01/2021 - 03/2012
7	Sorafenib (BAY 43-9006)FDA Link 01/2019 - 02/2008
7	Lenalidomide (CC 5013)FDA Link 01/2016 - 08/2006
7	Alemtuzumab (Campath)FDA Link 06/2013 - 05/2003
7	TransferasesIBA 11/2007 - 03/2003
6	bosutinibIBA 11/2023 - 08/2008
6	Inotuzumab OzogamicinIBA 01/2021 - 08/2013
6	Doxorubicin (Adriamycin)FDA LinkGeneric 05/2015 - 03/2002
6	Histone Deacetylase InhibitorsIBA 09/2012 - 08/2006
6	tipifarnib (R115777)IBA 03/2011 - 10/2002
5	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 01/2021 - 07/2002
5	BilirubinIBA 12/2018 - 04/2012
5	Reticulin (Reticular Fiber)IBA 01/2018 - 07/2004
5	Valproic Acid (Depakote)FDA LinkGeneric 02/2015 - 05/2005
5	Oncogene Proteins (Oncogene Protein)IBA 03/2011 - 04/2006
4	venetoclaxIBA 03/2024 - 03/2014
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2023 - 03/2002
4	DNA (Deoxyribonucleic Acid)IBA 10/2020 - 07/2009
4	blinatumomabIBA 01/2019 - 12/2017

Therapy/Procedure

230	Therapeutics 01/2024 - 03/2002
52	Drug Therapy (Chemotherapy) 07/2023 - 03/2002
18	Stem Cell Transplantation 02/2018 - 07/2003
13	Salvage Therapy 11/2020 - 04/2003
13	Induction Chemotherapy 01/2017 - 01/2003
9	Cell Transplantation 12/2020 - 09/2012
8	Drug Tapering 11/2021 - 06/2003
7	Hematopoietic Stem Cell Transplantation 08/2015 - 08/2004
6	Transplantation 05/2017 - 08/2004